MoonLake Immunotherapeutics Class A

XNASHealth care

Last traded price · USD

$11.48

−0.69%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:53 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $11.56
Volume: 1
Day's high: —
Day's low: —

In brief

MoonLake Immunotherapeutics is a health care company listed on Nasdaq, valued at about $977M.
Its shares closed at $11.56 on 4 Nov 2026, up 14.1% over the past year.
From India you can buy MLTX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy MoonLake Immunotherapeutics (MLTX) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole MLTX share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade MLTX options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

In line with SPY, behind its sector fund XLV over 1 year
1 month: +5.6% (SPY −1.6%, XLV +13.5%). 3 months: −34.1% (SPY −0.4%, XLV +15.5%). 1 year: +14.1% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: MLTX, SPY and XLV · as of 4 Nov 2026
Volume 2.2× its 30-session average on 29 Oct 2026
29 Oct 2026 volume of 4.1M shares was 2.2× the average of the 30 sessions before it (1.9M), as the price rose 2.1%. SPY traded 1.0× its own average that session.
Daily volume against a 30-session baseline · as of 29 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $11.56 was 5.9% below its 50-day average ($12.28) and 29.5% below its 200-day average ($16.39). It has closed below the 200-day for 54 sessions, since 20 Aug 2026. The 50-day average crossed below the 200-day on 17 Sep 2026, 34 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
15% of the way up its 52-week range
Closed at $11.56 on 4 Nov 2026: 50.4% below the 52-week high of $23.29 (22 Jun 2026) and 22.2% above the low of $9.46 (16 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Short interest at 9.2% of shares outstanding
7.8M shares were sold short at the 15 Oct 2026 settlement, 9.2% of the 85.1M shares outstanding; covering them would take 4.1 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+5.6%

6 months−34.7%

1 year+14.1%

5 years—

Newswire

About

MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.

Website

Notable moves

September 29, 2025
−89.93%
June 26, 2023
+77.55%
April 11, 2022
−39.00%

MoonLake Immunotherapeutics Class A

XNASHealth care

Last traded price · USD

$11.48

−0.69%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:53 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $11.56
Volume: 1
Day's high: —
Day's low: —

In brief

MoonLake Immunotherapeutics is a health care company listed on Nasdaq, valued at about $977M.
Its shares closed at $11.56 on 4 Nov 2026, up 14.1% over the past year.
From India you can buy MLTX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy MoonLake Immunotherapeutics (MLTX) shares from India?

Do I need the price of a whole MLTX share to invest?

How much can I invest in US stocks in a year?

Can I trade MLTX options or futures?

Insights

Quotes run fifteen minutes behind.

In line with SPY, behind its sector fund XLV over 1 year
1 month: +5.6% (SPY −1.6%, XLV +13.5%). 3 months: −34.1% (SPY −0.4%, XLV +15.5%). 1 year: +14.1% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: MLTX, SPY and XLV · as of 4 Nov 2026
Volume 2.2× its 30-session average on 29 Oct 2026
29 Oct 2026 volume of 4.1M shares was 2.2× the average of the 30 sessions before it (1.9M), as the price rose 2.1%. SPY traded 1.0× its own average that session.
Daily volume against a 30-session baseline · as of 29 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $11.56 was 5.9% below its 50-day average ($12.28) and 29.5% below its 200-day average ($16.39). It has closed below the 200-day for 54 sessions, since 20 Aug 2026. The 50-day average crossed below the 200-day on 17 Sep 2026, 34 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
15% of the way up its 52-week range
Closed at $11.56 on 4 Nov 2026: 50.4% below the 52-week high of $23.29 (22 Jun 2026) and 22.2% above the low of $9.46 (16 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Short interest at 9.2% of shares outstanding
7.8M shares were sold short at the 15 Oct 2026 settlement, 9.2% of the 85.1M shares outstanding; covering them would take 4.1 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+5.6%

6 months−34.7%

1 year+14.1%

5 years—

Newswire

About

Website

Notable moves

September 29, 2025
−89.93%
June 26, 2023
+77.55%
April 11, 2022
−39.00%

MoonLake Immunotherapeutics Class A

MoonLake Immunotherapeutics in brief

In line with SPY, behind its sector fund XLV over 1 year

Volume 2.2× its 30-session average on 29 Oct 2026

Below its 50- and 200-day averages

15% of the way up its 52-week range

Short interest at 9.2% of shares outstanding

MoonLake Immunotherapeutics Class A

MoonLake Immunotherapeutics in brief

In line with SPY, behind its sector fund XLV over 1 year

Volume 2.2× its 30-session average on 29 Oct 2026

Below its 50- and 200-day averages

15% of the way up its 52-week range

Short interest at 9.2% of shares outstanding